Black Diamond Therapeutics, Inc.Black Diamond Therapeutics, Inc.Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.43USD
Revenue estimate
Market capitalization
‪309.40 M‬USD
−1.92USD
‪−82.44 M‬USD
‪38.73 M‬
Beta (1Y)
4.39

About Black Diamond Therapeutics, Inc.

CEO
Mark A. Velleca
Headquarters
Cambridge
Employees (FY)
54
Founded
2014
FIGI
BBG00MS4Y0W9
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BDTX is 5.89 USD — it has increased by 15.26% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Black Diamond Therapeutics, Inc. stocks are traded under the ticker BDTX.
Black Diamond Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
BDTX stock is 16.28% volatile and has beta coefficient of 4.39. Check out the list of the most volatile stocks — is Black Diamond Therapeutics, Inc. there?
BDTX earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.49 USD resulting in a 7.53% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Black Diamond Therapeutics, Inc. earnings.
Yes, you can track Black Diamond Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BDTX stock has risen by 13.93% compared to the previous week, the month change is a 15.26% rise, over the last year Black Diamond Therapeutics, Inc. has showed a 303.42% increase.
BDTX net income for the last quarter is ‪−19.41 M‬ USD, while the quarter before that showed ‪−23.01 M‬ USD of net income which accounts for 15.64% change. Track more Black Diamond Therapeutics, Inc. financial stats to get the full picture.
Today Black Diamond Therapeutics, Inc. has the market capitalization of ‪309.40 M‬, it has decreased by 6.69% over the last week.
No, BDTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BDTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Black Diamond Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
BDTX reached its all-time high on Jun 3, 2020 with the price of 46.25 USD, and its all-time low was 1.18 USD and was reached on Oct 17, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has 54.00 employees. See our rating of the largest employees — is Black Diamond Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Black Diamond Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Black Diamond Therapeutics, Inc. stock shows the buy signal. See more of Black Diamond Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Black Diamond Therapeutics, Inc. future price: according to them, BDTX price has a max estimate of 16.00 USD and a min estimate of 10.00 USD. Read a more detailed Black Diamond Therapeutics, Inc. forecast: see what analysts think of Black Diamond Therapeutics, Inc. and suggest that you do with its stocks.